Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Babylon Holdings Limited stock logo
BBLN
Babylon
$0.55
$0.60
$0.46
$28.50
$14.10M2.42415,159 shsN/A
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
$0.00
$0.00
$0.03
$5K1.1916,004 shs5 shs
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
$3.72
-1.2%
$3.82
$2.21
$6.30
$137.99M-0.0582,238 shs37,131 shs
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
$1.12
$1.12
$0.63
$5.07
$13.13M2.29210,209 shsN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Babylon Holdings Limited stock logo
BBLN
Babylon
0.00%0.00%0.00%0.00%0.00%
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
0.00%0.00%-50.00%-66.67%-98.77%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
-3.99%-6.96%-5.74%-5.25%+54.27%
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Babylon Holdings Limited stock logo
BBLN
Babylon
N/AN/AN/AN/AN/AN/AN/AN/A
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
0.4917 of 5 stars
0.03.00.00.02.90.00.6
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Babylon Holdings Limited stock logo
BBLN
Babylon
0.00
N/AN/AN/A
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
0.00
N/AN/AN/A
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
4.00
Strong BuyN/AN/A
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Babylon Holdings Limited stock logo
BBLN
Babylon
$1.15B0.01N/AN/A($10.29) per share-0.05
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/AN/AN/AN/A
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
$4.01M34.41N/AN/A($0.30) per share-12.38
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
$3.88M3.38N/AN/A$1.37 per share0.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Babylon Holdings Limited stock logo
BBLN
Babylon
-$221.45M-$23.03N/AN/A-35.54%N/A-105.06%N/A
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
-$39.76MN/A0.00N/AN/AN/AN/AN/AN/A
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
-$10.04MN/A0.00N/AN/AN/AN/AN/A5/30/2025 (Estimated)
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
-$36.69MN/A0.00N/AN/AN/A-91.82%-64.58%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Babylon Holdings Limited stock logo
BBLN
Babylon
N/AN/AN/AN/AN/A
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/AN/AN/A
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
N/AN/AN/AN/AN/A
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Babylon Holdings Limited stock logo
BBLN
Babylon
N/A
1.07
1.07
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/A
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
N/A
0.13
N/A
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
N/A
3.51
3.51

Institutional Ownership

CompanyInstitutional Ownership
Babylon Holdings Limited stock logo
BBLN
Babylon
37.90%
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
34.00%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
4.35%
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
12.88%

Insider Ownership

CompanyInsider Ownership
Babylon Holdings Limited stock logo
BBLN
Babylon
38.52%
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
51.40%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
N/A
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Babylon Holdings Limited stock logo
BBLN
Babylon
1,89525.61 million15.75 millionNot Optionable
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
4049.86 million24.23 millionOptionable
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
237.15 millionN/ANot Optionable
Reunion Neuroscience Inc. stock logo
REUN
Reunion Neuroscience
1611.72 millionN/ANot Optionable

Recent News About These Companies

Twenty-First-Century Grief
Beethoven’s Ninth and the Ode to Joy: Symphony and Psyche

Media Sentiment Over Time

Babylon stock logo

Babylon NYSE:BBLN

Babylon Holdings Limited operates as a digital healthcare company. It offers end-to-end care solution that facilities through its digital health suite, virtual care, in-person medical care, and post-care offerings. The company provides Babylon Cloud and clinical services. Babylon Holdings Limited was founded in 2013 and is headquartered in Austin, Texas.

Better Therapeutics stock logo

Better Therapeutics NASDAQ:BTTX

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

EUDA Health stock logo

EUDA Health NASDAQ:EUDA

$3.72 -0.05 (-1.20%)
As of 09:40 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.

Reunion Neuroscience stock logo

Reunion Neuroscience NASDAQ:REUN

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.